Last reviewed · How we verify
ALMOTRIPTAN MALATE
Almotriptan malate is a selective 5-HT1B/1D receptor agonist that binds with high affinity to these receptors, leading to vasoconstriction and inhibition of neurogenic inflammation.
Almotriptan malate is a 5-HT1B/1D receptor agonist used for the acute treatment of migraine attacks in adults and adolescents aged 12 to 17 years. It is contraindicated in patients with ischemic heart disease, cerebrovascular syndromes, and uncontrolled hypertension. Common side effects include sensations of pain, tightness, pressure in the chest, throat, neck, and jaw. It should not be used within 24 hours of ergotamine-containing or other 5-HT1 agonist medications.
At a glance
| Generic name | ALMOTRIPTAN MALATE |
|---|---|
| Drug class | Triptan |
| Target | 5-HT1B/1D receptors |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 2001 |
Mechanism of action
Almotriptan malate exerts its therapeutic effects by selectively activating 5-HT1B/1D receptors, which are located on cranial blood vessels and sensory nerve endings. This activation leads to vasoconstriction and reduced release of inflammatory mediators, thereby alleviating migraine symptoms.
Approved indications
Boxed warnings
- Serious cardiac reactions, including myocardial infarction, have occurred following the use of almotriptan malate tablets. These reactions are extremely rare and most have been reported in patients with risk factors predictive of CAD.
Common side effects
- Sensations of pain, tightness, pressure in the chest and/or throat, neck, and jaw
Drug interactions
- undefined
- undefined
- undefined
- undefined
Key clinical trials
- ACT Therapy for HF Migraine (NA)
- Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine (PHASE4)
- Treatments of Migraine with Triptans in Individuals with Elevated Cardiovascular Risk and in Pregnant Women
- Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response? (PHASE4)
- Treximet ™ Pharmacy Budget Impact Model Database Validation Study
- Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine
- Standardized sTudy With Almotriptan in eaRly Treatment of Migraine
- A 1-year Study in Adolescents to Assess the Long-term Safety of Almotriptan Malate When Treating Their Migraine Headaches (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALMOTRIPTAN MALATE CI brief — competitive landscape report
- ALMOTRIPTAN MALATE updates RSS · CI watch RSS